Investigating how LINE-1 expression affects the immune response in ovarian cancer
Official title: Immunological consequences of LINE-1 expression in cancer
Funded at George Washington University · NIH-11052654 · Data updated 2026-11-12
This study is looking at how a specific part of our DNA, called LINE-1, affects the immune system in women with high-grade serous ovarian cancer, hoping to find new ways to improve treatments and help the body fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $632,855 |
| NIH project number | 5R01CA289390-02 |
| Project ID | NIH-11052654 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with high-grade serous ovarian cancer, particularly those with TP53 mutations.
✕Less likely to help
Patients with other types of cancer or those without TP53 mutations may not benefit from this research.
What this research studies
This research focuses on understanding the role of LINE-1, a type of transposable element, in ovarian cancer, particularly its impact on the immune system. The study examines how LINE-1 expression changes during the progression of high-grade serous ovarian cancer, which is characterized by mutations in the TP53 gene. By analyzing the relationship between LINE-1 activation and immune signaling, the research aims to uncover new therapeutic targets that could enhance anti-tumor responses. Patients may benefit from insights that could lead to novel treatments for ovarian cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates for ovarian cancer patients.
How similar studies have gone: Previous studies have shown promising results in understanding the role of transposable elements in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Chiappinelli, Katherine B — George Washington University
- Study coordinator: Chiappinelli, Katherine B
Related research
Other NIH-funded projects on the same topics.
-
HLA-F and KIR3DS1: unlocking NK cell help to control HIV
A short, patient-friendly look at how a specific immune interaction might help the body control HIV and reduce long-term health problems.
-
Emerging therapies for rare maternal mitochondrial diseases with shared causes
A basket clinical trial will test new drug candidates for two ultra-rare mitochondrial diseases (MELAS and LHON-Plus) that share the same underlying energy-making problem in people who could be affected.
-
Anti-cancer vaccine for liver fluke infection and bile duct cancer
A vaccine approach aims to stop liver fluke interactions with the human bile ducts to prevent bile duct cancer in regions where the parasite is common.
-
Anti-cancer vaccine targeting the host-parasite interface during liver fluke infection
A vaccine approach aims to block how a liver fluke parasite communicates with the human liver to prevent bile duct cancer in people in Southeast Asia.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A nationwide study aims to unravel why some teens with obesity develop type 2 diabetes while others don’t, and to identify factors that could help prevent it.
-
Ultrasensitive antibody-detection method to screen HIV-bNAbs
A new, ultra-sensitive test will help identify which broadly neutralizing antibodies can best block HIV-1 in people, by quickly checking how well these antibodies interact with the virus in patient-derived samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.